JAZZ vs. PRGO, CORT, HZNP, RDY, TEVA, UTHR, APLS, LEGN, VTRS, and SRPT
Should you be buying Jazz Pharmaceuticals stock or one of its competitors? The main competitors of Jazz Pharmaceuticals include Perrigo (PRGO), Corcept Therapeutics (CORT), Horizon Therapeutics Public (HZNP), Dr. Reddy's Laboratories (RDY), Teva Pharmaceutical Industries (TEVA), United Therapeutics (UTHR), Apellis Pharmaceuticals (APLS), Legend Biotech (LEGN), Viatris (VTRS), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical preparations" industry.
Jazz Pharmaceuticals vs.
Jazz Pharmaceuticals (NASDAQ:JAZZ) and Perrigo (NYSE:PRGO) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, community ranking, dividends, risk and profitability.
Jazz Pharmaceuticals has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500. Comparatively, Perrigo has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500.
In the previous week, Jazz Pharmaceuticals had 3 more articles in the media than Perrigo. MarketBeat recorded 9 mentions for Jazz Pharmaceuticals and 6 mentions for Perrigo. Jazz Pharmaceuticals' average media sentiment score of 0.96 beat Perrigo's score of 0.39 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media.
Jazz Pharmaceuticals received 310 more outperform votes than Perrigo when rated by MarketBeat users. Likewise, 80.40% of users gave Jazz Pharmaceuticals an outperform vote while only 66.97% of users gave Perrigo an outperform vote.
89.8% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 94.1% of Perrigo shares are owned by institutional investors. 4.4% of Jazz Pharmaceuticals shares are owned by insiders. Comparatively, 0.8% of Perrigo shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Perrigo has a net margin of -2.91% compared to Jazz Pharmaceuticals' net margin of -6.12%. Jazz Pharmaceuticals' return on equity of 24.04% beat Perrigo's return on equity.
Perrigo has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.
Jazz Pharmaceuticals presently has a consensus target price of $204.27, suggesting a potential upside of 48.76%. Perrigo has a consensus target price of $48.00, suggesting a potential upside of 45.45%. Given Jazz Pharmaceuticals' higher probable upside, equities research analysts clearly believe Jazz Pharmaceuticals is more favorable than Perrigo.
Summary
Jazz Pharmaceuticals beats Perrigo on 10 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding JAZZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Jazz Pharmaceuticals Competitors List